Latest Breaking News On - Zenasbiopharmaand linkedin - Page 1 : comparemela.com

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomMenlo parkUnited statesSan franciscoRock springsCity ofTel avivRedwood cityNew zealand generalNew zealandZenasbiopharmaand linkedinJake nunnZenas biopharmaTim xiaoEnterprise associates incEnavate sciences

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesHong kongBaden wübergSteve suginoZenasbiopharmaand linkedinZenas biopharmaBristol myers squibbBristol myers squibb companyXencor incRelated diseaseAuto immune hemolytic anemiaLonnie moulderChief executive officerSenior vice presidentGeneral manager

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD

Zenas biopharmaKostenloser wertpapierhandelZenasbiopharmaand linkedinXencor incGlobal phaseChief executive officerMedia contact

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Proceeds to fund global Phase 3 registration program for the company's lead product candidate, Obexelimab, and support the clinical development of other pipeline programsSeries B equity financing led by

New zealand generalNew zealandZenas biopharmaJim boylanTellus bioventuresKostenloser wertpapierhandelJames boylanHongbo luZenasbiopharmaand linkedinPatrick enrightXencor incQuan venture fundEnavate sciencesPatient square capitalLongitude capitalVivo capital

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products Obexelimab

United statesZenas biopharmaLauren bartlettBassil dahiyatCharles lilesZenasbiopharmaand linkedinXencor xmabExchange commissionXencor incCanale communicationsInhibitor fc domainPrivate securities litigation reform actInvestor contactMedia contact